CD39 and CD73 in immunity and inflammation

Trends in Molecular Medicine

Volumn 19, Issue 6, 2013, Pages 355-367

  Antonioli, Luca ^a,b   Pacher, Pál ^c   Vizi, E Sylvester ^d,e   Haskó, György ^b  

^a UNIVERSITY OF PISA   (Italy)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

CD39; CD73; Cytokine; Ectonucleotidase; Macrophage; Neutrophil; Sepsis; Treg

Indexed keywords

5' NUCLEOTIDASE; ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; CHEMOKINE; INTERFERON; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; APYRASE; LEUKOCYTE ANTIGEN;

ALLERGIC ENCEPHALOMYELITIS; ALLERGIC REACTION; ARTERY CALCIFICATION; ATHEROSCLEROSIS; BACTERIAL INFECTION; CATABOLISM; CELL INTERACTION; CHAGAS DISEASE; COLITIS; CONTACT ALLERGY; CROHN DISEASE; CYTOKINE RELEASE; CYTOLYSIS; DENDRITIC CELL; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXOCYTOSIS; GLOMERULONEPHRITIS; GLYCOSYLATION; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNITY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LEISHMANIASIS; LYMPHOCYTE; MACROPHAGE; METABOLIC DISORDER; MOLECULAR BIOLOGY; MONOCYTE; MULTIPLE SCLEROSIS; MYCOSIS; NEOPLASM; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARASITOSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FOLDING; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; TISSUE INJURY; TOXOPLASMOSIS; TUMOR MICROENVIRONMENT; VIRUS INFECTION; ANIMAL; ENZYMOLOGY; IMMUNOLOGY;

5'-NUCLEOTIDASE; ANIMALS; ANTIGENS, CD; APYRASE; HUMANS; IMMUNITY; INFLAMMATION;

EID: 84878614399     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.03.005     Document Type: Review

References (174)

1. Crimeen-Irwin B., et al. Failure of immune homeostasis - the consequences of under and over reactivity. Curr. Drug. Targets Immune Endocr. Metabol. Disord. 2005, 5:413-422.
2. Sitkovsky M.V., Ohta A. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors?. Trends Immunol. 2005, 26:299-304.
3. Haskó G., et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 2008, 7:759-770.
4. Trautmann A. Extracellular ATP in the immune system: more than just a 'danger signal'. Sci. Signal. 2009, 2:pe6.
5. Junger W.G. Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 2011, 11:201-212.
6. Sperlágh B., et al. ATP released by LPS increases nitric oxide production in raw 264.7 macrophage cell line via P2Z/P2X7 receptors. Neurochem. Int. 1998, 33:209-215.
7. Sperlágh B., et al. Potent effect of interleukin-1 beta to evoke ATP and adenosine release from rat hippocampal slices. J. Neuroimmunol. 2004, 151:33-39.
8. Sperlágh B., Vizi E.S. The role of extracellular adenosine in chemical neurotransmission in the hippocampus and basal ganglia: pharmacological and clinical aspects. Curr. Top. Med. Chem. 2011, 11:1034-1046.
9. Fredholm B.B., et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - an update. Pharmacol. Rev. 2011, 63:1-34.
10. Yegutkin G.G. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 2008, 1783:673-694.
11. Kukulski F., et al. Impact of ectoenzymes on p2 and p1 receptor signaling. Adv. Pharmacol. 2011, 61:263-299.
12. Schetinger M.R., et al. NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health. Biofactors 2007, 31:77-98.
13. Deaglio S., Robson S.C. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv. Pharmacol. 2011, 61:301-332.
14. Nikolova M., et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog. 2011, 7:e1002110.
15. Bönner F., et al. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. PLoS ONE 2012, 7:e34730.
16. Bastid J., et al. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 2012, 10.1038/onc.2012.269.
17. Zhang B. CD73 promotes tumor growth and metastasis. Oncoimmunology 2012, 1:67-70.
18. Heine P., et al. The C-terminal cysteine-rich region dictates specific catalytic properties in chimeras of the ectonucleotidases NTPDase1 and NTPDase2. Eur. J. Biochem. 2001, 268:364-373.
19. Maliszewski C.R., et al. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J. Immunol. 1994, 153:3574-3583.
20. Smith T.M., Kirley T.L. Cloning, sequencing, and expression of a human brain ecto-apyrase related to both the ecto-ATPases and CD39 ecto-apyrases1. Biochim. Biophys. Acta 1998, 1386:65-78.
21. Enjyoji K., et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat. Med. 1999, 5:1010-1017.
22. Zimmermann H. Two novel families of ectonucleotidases: molecular structures, catalytic properties and a search for function. Trends Pharmacol. Sci. 1999, 20:231-236.
23. Mizumoto N., et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat. Med. 2002, 8:358-365.
24. Kapojos J.J., et al. Enhanced ecto-apyrase activity of stimulated endothelial or mesangial cells is downregulated by glucocorticoids in vitro. Eur. J. Pharmacol. 2004, 501:191-198.
25. Dwyer K.M., et al. CD39 and control of cellular immune responses. Purinergic Signal. 2007, 3:171-180.
26. Eltzschig H.K., et al. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009, 113:224-232.
27. Chalmin F., et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012, 36:362-373.
28. Yegutkin G.G., et al. Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities. FASEB J. 2012, 26:3875-3883.
29. Sträter N. Ecto-5'-nucleotidase: structure function relationships. Purinergic Signal. 2006, 2:343-350.
30. Heuts D.P. Crystal structure of a soluble form of human CD73 with ecto-5' nucleotidase activity. Chembiochem 2012, 13:2384-2391.
31. Knapp K., et al. Crystal structure of the human ecto-5'-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure 2012, 20:2161-2173.
32. Thompson L.F., et al. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 2004, 200:1395-1405.
33. Lennon P.F., et al. Neutrophil-derived 5'-adenosine promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J. Exp. Med. 1998, 188:1433-1443.
34. Synnestvedt K. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 2002, 110:993-1002.
35. Eltzschig H.K., et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J. Exp. Med. 2003, 198:783-796.
36. Beavis P.A., et al. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 2012, 33:231-237.
37. Regateiro F.S., et al. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-beta. Eur. J. Immunol. 2011, 41:2955-2965.
38. Haskó G., Pacher P. Regulation of macrophage function by adenosine. Arterioscler. Thromb. Vasc. Biol. 2012, 32:865-869.
39. Mahamed D.A., et al. CD73-generated adenosine facilitates Toxoplasma gondii differentiation to long-lived tissue cysts in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:16312-16317.
40. Vignali D.A., et al. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523-532.
41. Mandapathil M., et al. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J. Immunol. Methods 2009, 346:55-63.
42. + T cells by magnetic beads reveals two phenotypically and functionally different subsets. J. Immunol. Methods 2011, 369:59-68.
43. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
44. Ernst P.B., et al. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J. Immunol. 2010, 185:1993-1998.
45. Deaglio S., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204:1257-1265.
46. Romio M., et al. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Am. J. Physiol. Cell Physiol. 2011, 301:C530-C539.
47. + regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front. Immunol. 2012, 3:190.
48. Kinsey G.R., et al. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J. Am. Soc. Nephrol. 2012, 23:1528-1537.
49. + T cells denotes a regulatory memory phenotype. Am. J. Transplant. 2010, 10:2410-2420.
50. + regulatory T cells. J. Biol. Chem. 2010, 285:7176-7186.
51. Antonioli L., et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr. Drug Targets 2012, 13:842-862.
52. Barletta K.E., et al. Regulation of neutrophil function by adenosine. Arterioscler. Thromb. Vasc. Biol. 2012, 32:856-864.
53. Chen Y., et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006, 314:1792-1795.
54. Eltzschig H.K., et al. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends Cardiovasc. Med. 2008, 18:103-107.
55. Haskó G., Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004, 25:33-39.
56. Pulte E.D., et al. CD39/NTPDase-1 activity and expression in normal leukocytes. Thromb. Res. 2007, 121:309-317.
57. Flögel U., et al. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci. Transl. Med. 2012, 4:146ra108.
58. Linden J. Cell biology. Purinergic chemotaxis. Science 2006, 314:1689-1690.
59. Eltzschig H.K., et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 2004, 104:3986-3992.
60. Kukulski F., et al. NTPDase1 controls IL-8 production by human neutrophils. J. Immunol. 2011, 187:644-653.
61. Corriden R., et al. Ecto-nucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J. Biol. Chem. 2008, 283:28480-28486.
62. Reutershan J., et al. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 2009, 23:473-482.
63. Eltzschig H.K., et al. Nucleotide metabolism and cell-cell interactions. Methods Mol. Biol. 2006, 341:73-87.
64. Lévesque S.A., et al. NTPDase1 governs P2X7-dependent functions in murine macrophages. Eur. J. Immunol. 2010, 40:1473-1485.
65. Haskó G., et al. Ecto-5'-nucleotidase (CD73) decreases mortality and organ injury in sepsis. J. Immunol. 2011, 187:4256-4267.
66. Petrovic-Djergovic D., et al. Tissue-resident ecto-5' nucleotidase (CD73) regulates leukocyte trafficking in the ischemic brain. J. Immunol. 2012, 188:2387-2398.
67. Zanin R.F., et al. Differential macrophage activation alters the expression profile of NTPDase and ecto-5'-nucleotidase. PLoS ONE 2012, 7:e31205.
68. Csóka B., et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J. 2012, 26:376-386.
69. Airas L., Jalkanen S. CD73 mediates adhesion of B cells to follicular dendritic cells. Blood 1996, 88:1755-1764.
70. Airas L. CD73 and adhesion of B-cells to follicular dendritic cells. Leuk. Lymphoma 1998, 29:37-47.
71. Verma S., Anderson T.J. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002, 105:546-549.
72. Packham M.A., Mustard J.F. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective. Semin. Thromb. Hemost. 2005, 3:129-138.
73. Atkinson B., et al. Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: potential as therapeutic targets. Blood Cells Mol. Dis. 2006, 36:217-222.
74. Fung C.Y., et al. P2X(1) receptor inhibition and soluble CD39 administration as novel approaches to widen the cardiovascular therapeutic window. Trends Cardiovasc. Med. 2009, 19:1-5.
75. Koszalka P., et al. Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ. Res. 2004, 95:814-821.
76. Salmi M., Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nat. Rev. Immunol. 2005, 5:760-771.
77. Takedachi M., et al. CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J. Immunol. 2008, 180:6288-6296.
78. Zernecke A., et al. CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation. Circulation 2006, 113:2120-2127.
79. Ålgars A., et al. Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood 2011, 117:4387-4393.
80. Kak V., et al. Immunotherapies in infectious diseases. Med. Clin. North Am. 2012, 96:455-474.
81. Paletta-Silva R., Meyer-Fernandes J.R. Adenosine and immune imbalance in visceral leishmaniasis: the possible role of ectonucleotidases. J. Trop. Med. 2012, 2012:650874.
82. Thammavongsa V., et al. Staphylococcus aureus synthesizes adenosine to escape host immune responses. J. Exp. Med. 2009, 206:2417-2427.
83. de Souza M.C., et al. The influence of ecto-nucleotidases on Leishmania amazonensis infection and immune response in C57B/6 mice. Acta Trop. 2010, 115:262-269.
84. Russo-Abrahão T., et al. Biochemical properties of Candida parapsilosis ecto-5'-nucleotidase and the possible role of adenosine in macrophage interaction. FEMS Microbiol. Lett. 2011, 317:34-42.
85. Fan J., et al. Ecto-5'-nucleotidase: a candidate virulence factor in Streptococcus sanguinis experimental endocarditis. PLoS ONE 2012, 7:e38059.
86. Théâtre E., et al. Overexpression of CD39 in mouse airways promotes bacteria-induced inflammation. J. Immunol. 2012, 189:1966-1974.
87. Tasca T., et al. Heterogeneity in extracellular nucleotide hydrolysis among clinical isolates of Trichomonas vaginalis. Parasitology 2005, 131:71-78.
88. Santos R.F., et al. Influence of ecto-nucleoside triphosphate diphosphohydrolase activity on Trypanosoma cruzi infectivity and virulence. PLoS Negl. Trop. Dis. 2009, 3:e387.
89. Russo-Abrahão T., et al. Giardia duodenalis: biochemical characterization of an ecto-5'-nucleotidase activity. Exp. Parasitol. 2011, 127:66-71.
90. Souza Vdo C., et al. E-NTPDase and E-ADA activities are altered in lymphocytes of patients within determinate form of Chagas' disease. Parasitol. Int. 2012, 61:690-696.
91. Oliveira C.B., et al. NTPDase activity in lymphocytes of rats infected by Trypanosoma evansi. Parasitology 2012, 139:232-236.
92. Sansom F.M., et al. A bacterial ecto-triphosphate diphosphohydrolase similar to human CD39 is essential for intracellular multiplication of Legionella pneumophila. Cell. Microbiol. 2007, 9:1922-1935.
93. Yegutkin G.G., et al. Disordered lymphoid purine metabolism contributes to the pathogenesis of persistent Borrelia garinii infection in mice. J. Immunol. 2010, 184:5112-5120.
94. Alam M.S., et al. CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J. Infect. Dis. 2009, 199:494-504.
95. Kas-Deelen A.M., et al. Cytomegalovirus infection increases the expression and activity of ecto-ATPase (CD39) and ecto-5'nucleotidase (CD73) on endothelial cells. FEBS Lett. 2001, 491:21-25.
96. Leal D.B., et al. HIV infection is associated with increased NTPDase activity that correlates with CD39-positive lymphocytes. Biochim. Biophys. Acta 2005, 1746:129-134.
97. + T regulatory cells correlates with progressive disease. J. Virol. 2011, 85:1287-1297.
98. Mills J.H., et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9325-9330.
99. Thompson L.F., et al. Regulation of leukocyte migration across endothelial barriers by ECTO-5'-nucleotidase-generated adenosine. Nucleosides Nucleotides Nucleic Acids 2008, 27:755-760.
100. Mills J.H., et al. Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis. J. Neuroinflamm. 2012, 9:193.
101. Airas L., et al. Mechanism of action of IFN-beta in the treatment of multiple sclerosis: a special reference to CD73 and adenosine. Ann. N. Y. Acad. Sci. 2007, 1110:641-648.
102. Niemelä J., et al. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur. J. Immunol. 2008, 38:2718-2726.
103. + regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 2009, 183:7602-7610.
104. + regulatory T cell population during remission but not during relapse. J. Neuroimmunol. 2011, 240-241:97-103.
105. Moncrieffe H., et al. High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J. Immunol. 2010, 185:134-143.
106. Montesinos M.C., et al. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. Arthritis Rheum. 2007, 56:1440-1445.
107. Nekooeian A.A., Tabrizchi R. Effects of adenosine A2A receptor agonist, CGS 21680, on blood pressure, cardiac index and arterial conductance in anaesthetized rats. Eur. J. Pharmacol. 1996, 307:163-169.
108. Nair P.K., et al. Clinical utility of regadenoson for assessing fractional flow reserve. JACC Cardiovasc. Interv. 2011, 4:1085-1092.
109. Blume C., et al. Autoimmunity in CD73/ecto-5'-nucleotidase deficient mice induces renal injury. PLoS ONE 2012, 7:e3710.
110. Friedman D.J., et al. From the cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:16788-16793.
111. Bynoe M.S., et al. CD73 is critical for the resolution of murine colonic inflammation. J. Biomed. Biotechnol. 2012, 2012:260983.
112. Thompson L.F., et al. Animal models of airway diseases. Subcell. Biochem. 2011, 55:195-234.
113. Schreiber R., et al. Allergen-induced airway hyperresponsiveness is absent in ecto-5'-nucleotidase(CD73)-deficient mice. Pflugers Arch. 2008, 457:431-440.
114. + regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism. J. Allergy Clin. Immunol. 2009, 123:1287-1296.
115. Eckle T., et al. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007, 115:1581-1590.
116. Kohler D., et al. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 2007, 116:1784-1794.
117. Grenz A., et al. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med. 2008, 5:e137.
118. Grenz A., et al. Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia. J. Am. Soc. Nephrol. 2007, 18:833-845.
119. Grenz A., et al. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J. 2007, 21:2863-2873.
120. Jian R., et al. CD73 protects kidney from ischemia-reperfusion injury through reduction of free radicals. APMIS 2012, 120:130-138.
121. Hart M.L., et al. Extracellular adenosine production by ecto-5'-nucleotidase protects during murine hepatic ischemic preconditioning. Gastroenterology 2008, 135:1739-1750.
122. Hart M.L., et al. SP1-dependent induction of CD39 facilitates hepatic ischemic preconditioning. J. Immunol. 2011, 184:4017-4024.
123. Sun X., et al. Liver damage and systemic inflammatory responses are exacerbated by the genetic deletion of CD39 in total hepatic ischemia. Purinergic Signal. 2011, 7:427-434.
124. + T cells. Hepatology 2013, 57:1597-1606.
125. Hart M.L., et al. Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury. FASEB J. 2008, 22:2784-2797.
126. Hart M.L., et al. Hypoxia-inducible factor-1α-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5'-nucleotidase (CD73) and the A2B adenosine receptor. J. Immunol. 2011, 186:4367-4374.
127. Böring Y.C., et al. Lack of ecto-5'-nucleotidase (CD73) promotes arteriogenesis. Cardiovasc. Res. 2012, 97:88-96.
128. Crikis S., et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am. J. Transplant. 2010, 10:2586-2595.
129. Wierda R.J., et al. Epigenetics in atherosclerosis and inflammation. J. Cell. Mol. Med. 2010, 14:1225-1240.
130. Di Virgilio F., Solini A. P2 receptors: new potential players in atherosclerosis. Br. J. Pharmacol. 2002, 135:831-842.
131. Reiss A.B., Cronstein B.N. Regulation of foam cells by adenosine. Arterioscler. Thromb. Vasc. Biol. 2012, 32:879-886.
132. Mercier N., et al. Impaired ATP-induced coronary blood flow and diminished aortic NTPDase activity precede lesion formation in apolipoprotein E-deficient mice. Am. J. Pathol. 2012, 180:419-428.
133. Behdad A., et al. Vascular smooth muscle cell expression of ectonucleotidase CD39 (ENTPD1) is required for neointimal formation in mice. Purinergic Signal. 2009, 5:335-342.
134. Buchheiser A., et al. Inactivation of CD73 promotes atherogenesis in apolipoprotein E-deficient mice. Cardiovasc. Res. 2011, 92:338-347.
135. Rutsch F., et al. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ. Res. 2011, 109:578-592.
136. Fish R.S., et al. ATP and arterial calcification. Eur. J. Clin. Invest. 2013, 43:405-412.
137. St Hilaire C., et al. NT5E mutations and arterial calcifications. N. Engl. J. Med. 2011, 364:432-442.
138. Markello T.C., et al. Vascular pathology of medial arterial calcifications in NT5E deficiency: implications for the role of adenosine in pseudoxanthoma elasticum. Mol. Genet. Metab. 2011, 103:44-50.
139. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998, 15:539-553.
140. Chia J.S., et al. The protective effects of CD39 over-expression in multiple low dose streptozotocin-induced diabetes in mice. Diabetes 2013, 10.2337/db12-0625.
141. Németh Z.H., et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J. 2007, 21:2379-2388.
142. Enjyoji K., et al. Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes 2008, 57:2311-2320.
143. García-Hernández M.H., et al. Expression and function of P2X(7) receptor and CD39/Entpd1 in patients with type 2 diabetes and their association with biochemical parameters. Cell. Immunol. 2011, 269:135-143.
144. Burghoff S., et al. Deletion of CD73 promotes dyslipidemia and intramyocellular lipid accumulation in muscle of mice. Arch. Physiol. Biochem 2013, 10.3109/13813455.2012.755547.
145. Chew V., et al. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J. Oncol. 2012, 2012:608406.
146. Yaqub S., Aandahl E.M. Inflammation versus adaptive immunity in cancer pathogenesis. Crit. Rev. Oncog. 2009, 15:43-63.
147. neg T-cell subsets in cancer patients. Immunity 2012, 36:362-373.
148. Sun H.L., et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J. Gastroenterol. 2012, 18:3303-3309.
149. Zhang B. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS ONE 2013, 8:e57114.
150. Clayton A., et al. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol. 2011, 187:676-683.
151. Zhou X., et al. Effects of ecto-5'-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol. Rep. 2007, 17:1341-1346.
152. + regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 2010, 139:1030-1040.
153. Künzli B.M., et al. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G223-G230.
154. Stagg J., et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011, 71:2892-2900.
155. Serra S., et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 2011, 118:6141-6152.
156. Sadej R., et al. Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res. 2006, 16:213-222.
157. Stagg J., et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1547-1552.
158. Jackson S.W., et al. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am. J. Pathol. 2007, 171:1395-1404.
159. Feng L., et al. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 2011, 13:206-216.
160. Goepfert C., et al. Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 2001, 104:3109-3115.
161. Wink M.R., et al. Thyroid hormone upregulates ecto-5'-nucleotidase/CD73 in C6 rat glioma cells. Mol. Cell. Endocrinol. 2003, 205:107-114.
162. Mandapathil M., et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin. Cancer Res. 2009, 15:6348-6357.
163. Dzhandzhugazyan K.N., et al. Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Lett. 1998, 430:227-230.
164. Kondo T., et al. Expression of CD73 and its ecto-5'-nucleotidase activity are elevated in papillary thyroid carcinomas. Histopathology 2006, 48:612-614.
165. Buffon A., et al. NTPDase and 5' ecto-nucleotidase expression profiles and the pattern of extracellular ATP metabolism in the Walker 256 tumor. Biochim. Biophys. Acta 2007, 1770:1259-1265.
166. Zhi X., et al. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer. IUBMB Life 2012, 64:911-920.
167. Künzli B.M., et al. Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal. 2011, 7:231-241.
168. Wu X.R., et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J. Surg. Oncol. 2012, 106:130-137.
169. Stella J., et al. Differential ectonucleotidase expression in human bladder cancer cell lines. Urol. Oncol. 2010, 28:260-267.
170. Häusler S.F., et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol. Immunother. 2011, 60:1405-1418.
171. Stagg J., et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 2012, 72:2190-2196.
172. Pulte D., et al. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia. J. Transl. Med. 2007, 5:23.
173. + T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia. Ann. Hematol. 2012, 91:1271-1279.
174. +-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. J. Immunol. 2009, 183:6157-6166.